Curr Oncol Rep 2021 Aug 4;23(10):120. Epub 2021 Aug 4.
Division of Medical Oncology and Hematology, University Health Network - Princess Margaret Cancer Centre, 610 University Avenue, 700 U 6th Floor, Toronto, Ontario, M5G 2M9, Canada.
Purpose Of Review: With the recent approval of multiple new drugs for the treatment of acute myeloid leukemia (AML), the relevance of conventional treatment approaches, such as daunorubicin and cytarabine ("3+7") induction chemotherapy, has been challenged. We review the AML risk stratification, the efficacy of the newly approved drugs, and the role of "3+7".
Recent Findings: Treatment of AML is becoming more niched with specific subtypes more appropriately treated with gemtuzumab, midostaurin, and CPX-351. Read More